- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Profusa, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | What's Going On With Profusa Stock Tuesday? | 2 | Benzinga.com | ||
| 06.04. | Profusa Stock Soars On Deal Targeting Multi Billion Precision Diagnostics Space | 2 | Benzinga.com | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| 06.04. | Profusa plant Übernahme von Diagnostik-Plattform und kooperiert mit Mayo Clinic - Aktie steigt um 45 % | 3 | Investing.com Deutsch | ||
| 06.04. | Profusa to acquire multi-omics platform, partners with Mayo Clinic | 1 | Investing.com | ||
| 06.04. | Profusa, Inc.: Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform | 384 | GlobeNewswire (Europe) | Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications... ► Artikel lesen | |
| 06.04. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.02. | Profusa sagt öffentliches Angebot über 15 Mio. USD ab und plant kleinere Finanzierungsrunde | 3 | Investing.com Deutsch | ||
| 27.02. | Profusa cancels $15M public offering, plans smaller fundraise | 3 | Investing.com | ||
| 27.02. | Profusa, Inc.: Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering | 680 | GlobeNewswire (Europe) | After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to... ► Artikel lesen | |
| 19.02. | Profusa raises 2026 revenue forecast on European purchase orders | 1 | Investing.com | ||
| 17.02. | Profusa, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.02. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Profusa, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 13.02. | Profusa, Mayo Clinic collab on oxygen monitoring tech | 4 | MassDevice | ||
| 12.02. | Profusa, Inc.: Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies | 3 | GlobeNewswire (USA) | ||
| 05.02. | Profusa, Inc.: Profusa Announces 1-for-75 Reverse Stock Split | 270 | GlobeNewswire (Europe) | BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform... ► Artikel lesen | |
| 02.02. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.01. | Profusa, Inc.: Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 | 3 | GlobeNewswire (USA) | ||
| 16.01. | Profusa Stock Spikes As Lumee System Targets Research Market | 3 | Benzinga.com |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 4,760 | +1,47 % | Teladoc Health, Inc.: Teladoc Health to Announce First Quarter 2026 Financial Results | ||
| HIMS & HERS HEALTH | 22,300 | +8,25 % | Hims & Hers-Aktie: Neue Chancen nach dem Hype? | Die Aktie von Hims & Hers Health hat nach einer Zeit voller Hype und überschwänglichen Erwartungen in den vergangenen Monaten massiv gelitten. Nach einem deutlichen Kursrückgang rückt nun die Frage... ► Artikel lesen | |
| PLUS THERAPEUTICS | 5,640 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution | HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| HEALWELL AI | 0,534 | -1,11 % | Bloom Burton & Co. Inc.: HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference | 2026 Bloom Burton & Co. Healthcare Investor Conference on April 21-22, 2026, in Toronto, ONToronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL"... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,420 | 0,00 % | Co-Diagnostics Reports Full Year 2025 Financial Results | Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures
Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform
Strengthening... ► Artikel lesen | |
| VERU | 2,440 | 0,00 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| SENSEONICS | 5,800 | -0,85 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| ELEKTA | 5,270 | 0,00 % | Dividendenbekanntmachungen (05.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERICAN ASSETS TRUST INC US0240131047 0,34 USD 0,2922 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2914 EUR ASSOCIATED... ► Artikel lesen | |
| IMUNON | 2,460 | +1,65 % | Imunon, Inc.: IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study | IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 3,700 | +1,09 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results | Lead program VMT-a-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported... ► Artikel lesen | |
| AXE COMPUTE | 2,840 | 0,00 % | Axe Compute Inc. Reports Full-Year 2025 Financial Results | Completed Strategic Transformation to AI Compute Infrastructure Raised $343.5 Million in Capital to Fund Digital Asset Treasury Strategy Solidified new leadership composition with world class CEO... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 25,700 | 0,00 % | PROCEPT BioRobotics to Report First Quarter 2026 Financial Results on April 29, 2026 | ||
| AXOGEN | 29,380 | -0,24 % | Axogen, Inc.: Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock | ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral... ► Artikel lesen | |
| MYOMO | 0,676 | 0,00 % | Myomo outlines 10% revenue growth target for 2026 while expanding recurring patient sources and international operations | ||
| MEDLINE | 39,000 | -4,41 % | FDA Flags Quality System Lapses At Medline Facility Over Device Risks |
Das Unternehmen PROFUSA INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,650 Euro und damit -6,46 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.